Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101

Immunotherapy approaches focusing on T cells have provided breakthroughs in treating solid tumors. However, there remains an opportunity to drive anticancer immune responses via other cell types, particularly myeloid cells. ATRC-101 was identified via a target-agnostic process evaluating antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Scholz, Alexander, DeFalco, Jeff, Leung, Yvonne, Aydin, Iraz T., Czupalla, Cathrin J., Cao, Wei, Santos, Daniel, Vad, Nikhil, Lippow, Shaun M., Baia, Gilson, Harbell, Michael, Sapugay, Judevin, Zhang, Danhui, Wu, Dai-Chen, Wechsler, Erin, Ye, Anne Z., Wu, Jenny W., Peng, Xiao, Vivian, John, Kaplan, Hargita, Collins, Rodney, Nguyen, Ngan, Whidden, Mark, Kim, Dongkyoon, Millward, Carl, Benjamin, Jonathan, Greenberg, Norman M., Serafini, Tito A., Emerling, Daniel E., Steinman, Lawrence, Robinson, William H., Manning-Bog, Amy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171637/
https://www.ncbi.nlm.nih.gov/pubmed/35507878
http://dx.doi.org/10.1073/pnas.2123483119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171637/
https://www.ncbi.nlm.nih.gov/pubmed/35507878
http://dx.doi.org/10.1073/pnas.2123483119

Ejemplares similares